A Nanjing Suzhong Pharmaceutical Research Co. Ltd. and Suzhong Pharmaceutical Group Co. Ltd. patent describes phenyl-substituted dihydronaphthyridine compounds acting as mineralocorticoid receptor (MR) antagonists potentially useful for the treatment of aldosteronism, cirrhosis, diabetic nephropathy, heart failure, hypertension, myocardial infarction, renal failure and stroke.

Rpxds Co. Ltd. has identified new α-ketoglutarate-dependent dioxygenase FTO inhibitors acting as serum LDL-, cholesterol- and triglyceride-lowering agents and thus reported to be useful for the treatment of obesity, Alzheimer’s disease and obesity-related disorders.

Rezolute Inc. has patented new plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of diabetic macular edema, diabetic retinopathy and uveitis.

After more than a decade of industry pleading for guidance on Orange Book patent listings, the U.S. FDA is finally planning on answering that request this year. If the guidance that’s produced reflects the FTC’s position that device patents can’t be listed for combination products, it could overturn years of accepted practice and possibly hinder the development of new, more advanced drug administration technologies.

Chiesi Farmaceutici SpA has detailed new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).

Work at Abbisko Therapeutics Co. Ltd. has led to the identification of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors potentially useful for the treatment of cancer.

Shouyao Holdings (Beijing) Co. Ltd. has patented tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer and Noonan syndrome.

Kinesin-like protein KIF18A inhibitors have been reported in a Humanwell Healthcare (Group) Co. Ltd. patent and are described as potentially useful for the treatment of atopic dermatitis, autoimmune disease, cancer, Crohn’s disease, psoriasis and ulcerative colitis.

Baylor College of Medicine has disclosed new neurotrophic receptor tyrosine kinase (NTRK) inhibitors that are reported to be useful for the treatment of cancer, endometriosis, female infertility, pelvic pain and inflammatory disorders.

Anadolu University and Atatürk University have jointly described novel 3,5-disubstituted-1,2,4-oxadiazole derived compounds acting as carbonic anhydrase type I and/or type II inhibitors.